CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results

Daniels, Craig E., Lasky, Joseph A., Limper, Andrew H., Mieras, Kathleen, Gabor, Edith, Schroeder, Darrell R. · 2010 · American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with no known efficacious therapy. Imatinib is a tyrosine kinase inhibitor with potential efficacy to treat fibrotic lung disease. Objectives: To investigate the safety and clinical effects of imatinib in patients with IPF. Methods: We studied 119 patients in an investigator-initiated, multicenter, multinational, double-blind clinical trial to receive imatinib or placebo for 96 weeks. Measurements and Main Results: Over 96 weeks of follow-up, imatinib did not differ significantly from placebo (log rank P = 0.89) for the primary endpoint defined as time to disease progression (10% decline in percent predicted FVC from baseline) or time to death. There was no effect of imatinib therapy on change in FVC at 48, 72, or 96 weeks (P ≥ 0.39 at all time points) or change in diffusing capacity of carbon monoxide at 48, 72, or 96 weeks (P ≥ 0.26 at all time points). Change in resting PaO2 favored imatinib therapy at 48 weeks (P = 0.005) but not at 96 weeks (P = 0.074). During the 96-week trial there were 8 deaths in the imatinib group and 10 deaths in the placebo group (log rank test P = 0.64). Thirty-five (29%) patients discontinued the study without reaching the primary endpoint (imatinib, 32%; placebo, 27%; P = 0.51). Serious adverse events (SAEs) were not more common in the imatinib group (imatinib, 18 SAEs in 17 patients; placebo, 19 SAEs in 18 patients). Conclusions: In a randomized, placebo-controlled trial of patients with mild to moderate IPF followed for 96 weeks, imatinib did not affect survival or lung function. Clinical trial registered with www.clinicaltrials.gov (NCT00131274).

Overview

Integrity signals

Registry

Crossref · 10.1164/rccm.200906-0964oc

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 33

  1. 2000, Am J Respir Crit Care Med, 646
  2. 2006, Proc Am Thorac Soc, 364
  3. 2007, Eur Respir J, 835
  4. 2005, Crit Rev Immunol, 429
  5. 2005, Am J Respir Crit Care Med, 417
  6. 2008, Eur J Pharmacol, 44
  7. 2002, Eur J Cancer, S28
  8. 2002, N Engl J Med, 683
  9. 2006, N Engl J Med, 1278
  10. 2005, N Engl J Med, 1412
  11. 2004, J Clin Invest, 1308
  12. 2007, Am J Respir Crit Care Med, 1243
  13. 2005, Am J Respir Crit Care Med, 1279
  14. 2004, N Engl J Med, 125
  15. 2008, Am J Respir Crit Care Med, 75
  16. 2008, Am J Respir Crit Care Med, 948
  17. 2006, Am J Respir Crit Care Med, 810
  18. 2007, Am J Respir Crit Care Med, 636
  19. 2008, Respiration, 350
  20. 2004, Leukemia, 645
  21. 2008, Eur Respir J, 170
  22. 2007, Am J Respir Cell Mol Biol, 291
  23. 2005, Circ Res, 784
  24. 2005, J Clin Invest, 2811
  25. 2006, Br J Clin Pharmacol, 97
  26. 2002, Am J Respir Crit Care Med, 277
  27. 2007, Am J Respir Crit Care Med, 1054
  28. 2005, N Engl J Med, 2229
  29. 2005, Am J Respir Crit Care Med, 1040
  30. 2006, Curr Mol Med, 409
  31. 2008, Arthritis Rheum, 2538
  32. 2008, Eur Respir J, 232
  33. 2004, Inflamm Res, 133

Cited by

See all 381

Metadata

Authors
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R.
Affiliations
  • Mayo Clinic (US)
  • Tulane University (US)
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2010-03
Volume
181
Issue
6
Pages
604-610
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2111459732
Cited by
373
References
34
Citations by year
2026: 8 · 2025: 10 · 2024: 11 · 2023: 7 · 2022: 15 · 2021: 10 · 2020: 17 · 2019: 12 · 2018: 25 · 2017: 27 · 2016: 29 · 2015: 39 · 2014: 19 · 2013: 43 · 2012: 42
FWCI
27.88
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, imatinib, tyrosine kinase inhibitors, pulmonary fibrosis, forced vital capacity decline, mortality, diffusing capacity for carbon monoxide, arterial oxygenation, drug safety, treatment efficacy
MeSH terms
Imatinib Mesylate, Aged, Anemia, Benzamides, Double-Blind Method, Dyspnea, Feasibility Studies, Female, Follow-Up Studies, Gastrointestinal Diseases, Hematoma, Subdural, Humans, Leukopenia, Male, Middle Aged, Piperazines, Pyrimidines, Respiratory Function Tests, Survival Analysis, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results. https://app.cochat.ai/papers/10.1164/rccm.200906-0964oc
The paper
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010). Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200906-0964oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.